2nd Quarter Results for FY2017 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Global Finance, IR TEL: +81-3-3278-2306 http://www.takeda.com/ Quarterly Announcements / Presentations https://www.takeda.com/investors/reports/quarterly-announcements/ Contents I. Financial Results 1. Segment Information 1 2. Revenue by Region ◆ Consolidated Revenue (Prescription Drugs + Consumer Healthcare + Other) 3 ◆ Consolidated Prescription Drugs Revenue 3 ◆ Consolidated Revenue (Quarterly: Prescription Drugs + Consumer Healthcare + Other) 4 ◆ Consolidated Prescription Drugs Revenue (Quarterly) 4 ◆ Prescription Drugs: Global major products' sales 5 ◆ Prescription Drugs: Global major products' sales (Quarterly) 6-7 3. Exchange Rate 8 II. Pipeline 1. Development Activities 9-12 ■ Oncology ■ Gastroenterology ■ CNS ■ Vaccines ■ Others 2. Recent progress in stage 11 3. Discontinued projects 11 4. Externalized assets in which Takeda retains a financial interest 12 5. Research & Development collaborations 12-13 ■ Clinical study protocol summaries 13 Appendix ◆ Prescription Drugs: US major products' sales (in US$) 14 ◆ Prescription Drugs: US major products' sales (in US$) (Quarterly) 15 ◆ Prescription Drugs: Japan major products' sales 16 ◆ Prescription Drugs: Japan major products' sales (Quarterly) 17 ◆ Consumer Healthcare: Japan major products' sales 18 ◆ Consumer Healthcare: Japan major products' sales (Quarterly) 19 I. Financial Results 1. Segment Information (Billion JPY) FY16 FY17 FY17 FY14 FY15 FY16 YOY Q2YTD Q2YTD Forecasts Revenue 1,777.8 1,807.4 1,732.1 850.8 881.4 30.6 3.6% 1,720.0 Prescription drugs 1,614.5 1,648.7 1,568.9 769.7 838.4 68.7 8.9% Consumer healthcare 73.6 80.1 82.6 42.3 42.7 0.4 0.9% Other 89.7 78.6 80.6 38.8 0.3 -38.5 -99.3% Operating Profit -129.3 130.8 155.9 162.1 234.3 72.3 44.6% 200.0 Prescription drugs -178.9 102.8 128.4 146.3 101.2 -45.1 -30.8% <% of Prescription drugs revenue> <-11.1%> <6.2%> <8.2%> <19.0%> <12.1%> < 6.9pt> △ Consumer healthcare 17.2 18.9 20.5 12.1 12.1 0.0 0.0% <% of Consumer healthcare revenue> <23.4%> <23.6%> <24.9%> <28.5%> <28.3%> <-0.2pt> Other 32.4 9.1 6.9 3.7 121.1 117.4 - <% of Other revenue> <36.2%> <11.5%> <8.6%> <9.6%> - - 1 ◆Segment Information (Quarterly) (Billion JPY) FY16 FY17 Q1 Q2 Q3 Q4 Q1 YOY Q2 YOY Q3 YOY Q4 YOY Revenue 434.0 416.8 465.0 416.2 448.2 3.3% 433.2 3.9% -881.4 - - Prescription drugs 394.0 375.6 421.0 378.1 427.2 8.4% 411.2 9.5% -838.4 - - Consumer healthcare 20.4 22.0 23.1 17.1 20.9 2.3% 21.9 -0.4% -42.7 - - Others 19.6 19.2 20.9 20.9 0.1 -99.3% 0.1 -99.3% -0.3 - - Operating Profit 152.9 9.1 55.4 -61.6 195.0 27.5% 39.4 - -234.3 - - Prescription drugs 142.2 4.1 46.3 -64.2 66.8 -53.0% 34.3 - -101.2 - - <% of Prescription drugs revenue> <36.1%> <1.1%> <11.0%> <-17.0%> <15.6%> <8.3%> <12.1%> #DIV/0! Consumer healthcare 7.4 4.7 6.9 1.6 6.6 -10.4% 5.5 16.5% -12.1 - - <% of Consumer healthcare revenue> <36.2%> <21.4%> <29.8%> <9.1%> <31.7%> <25.0%> <28.3%> #DIV/0! Others 3.3 0.4 2.1 1.1 121.5 - -0.4 - -121.1 - - <% of Others revenue> <17.1%> <2.0%> <10.2%> <5.2%> - - ######## #DIV/0! 2 2. Revenue by Region ◆Consolidated Reveue (Prescription drugs + Consumer healthcare + Other) (Billion JPY) FY16 FY17 FY14 FY15 FY16 YOY Q2YTD Q2YTD Total revenue 1,777.8 1,807.4 1,732.1 850.8 881.4 30.6 3.6% Japan 712.8 688.1 655.3 327.1 295.0 -32.1 -9.8% <% of revenue> <40.1%> <38.1%> <37.8%> <38.4%> <33.5%> <-5.0pt> United States 426.1 514.4 520.2 251.9 301.8 49.9 19.8% <% of revenue> <24.0%> <28.5%> <30.0%> <29.6%> <34.2%> <4.6pt> Europe and Canada 325.3 309.3 279.7 142.8 148.9 6.2 4.3% <% of revenue> <18.3%> <17.1%> <16.1%> <16.8%> <16.9%> <0.1pt> Emerging Markets 313.6 295.6 276.9 129.0 135.7 6.7 5.2% <% of revenue> <17.6%> <16.4%> <16.0%> <15.2%> <15.4%> <0.2pt> Russia/CIS 81.3 61.8 57.5 25.5 35.1 9.6 37.8% <% of revenue> <4.6%> <3.4%> <3.3%> <3.0%> <4.0%> <1.0pt> Latin America 85.4 68.4 72.5 31.7 36.1 4.4 13.8% <% of revenue> <4.8%> <3.8%> <4.2%> <3.7%> <4.1%> <0.4pt> Asia 111.4 126.0 112.8 55.5 49.2 -6.3 -11.3% <% of revenue> <6.3%> <7.0%> <6.5%> <6.5%> <5.6%> <-0.9pt> Other 35.5 39.4 34.0 16.4 15.3 -1.0 -6.3% <% of revenue> <2.0%> <2.2%> <2.0%> <1.9%> <1.7%> <-0.2pt> Royalty income and service income 87.5 56.5 60.1 29.2 43.2 14.0 48.0% *1 Revenue amount is classified into countries or regions based on the customer location. *2 Other region includes Middle East, Oceania and Africa. ◆ Consolidated Prescription Drugs Revenue (Billion JPY) FY16 FY17 Underlying FY14 FY15 FY16 YOY Q2YTD Q2YTD Growth Total prescription drugs revenue 1,614.5 1,648.7 1,568.9 769.7 838.4 68.7 8.9% 7.0% Japan 561.3 541.7 504.7 251.7 252.0 0.3 0.1% 0.3% United States 419.5 511.0 516.7 250.3 301.8 51.5 20.6% 16.7% Europe and Canada 326.7 305.6 276.0 141.0 148.9 7.9 5.6% 4.2% Emerging Markets 307.0 290.4 271.5 126.7 135.7 9.1 7.1% 3.4% Russia/CIS 81.2 61.8 57.5 25.5 35.1 9.6 37.8% 21.7% Russia 57.6 43.5 41.9 18.6 26.3 7.7 41.3% 21.1% Latin America 85.0 68.2 72.5 31.7 36.1 4.4 13.9% 10.0% Brazil 47.6 38.1 39.0 18.0 21.9 4.0 22.0% 12.1% Asia 106.6 121.2 107.8 53.2 49.2 -4.0 -7.5% -8.8% China 55.2 66.0 57.6 28.6 22.7 -6.0 -20.9% -20.2% Other 34.3 39.2 33.7 16.3 15.3 -1.0 -6.0% -1.8% Royalty income and service income 86.9 55.8 59.5 28.8 42.9 14.0 48.7% -3.0% Japan 8.1 6.6 18.7 12.3 20.6 8.3 67.2% -12.0% Overseas 78.8 49.3 40.9 16.5 22.3 5.8 34.9% -0.4% Ratio of overseas prescription drugs 65.2% 67.1% 67.8% 67.3% 69.9% <2.7pt> *1 Revenue amount is classified into countries or regions based on the customer location. *2 Other region includes Middle East, Oceania and Africa. 3 ◆Consolidated Revenue (Quarterly: Prescription drugs + Consumer healthcare + Other) (Billion JPY) FY16 FY17 Q1 Q2 Q3 Q4 Q1 YOY Q2 YOY Q3 YOY Q4 YOY Total revenue 434.0 416.8 465.0 416.2 448.2 3.3% 433.2 3.9% -881.4 - - Japan 163.8 163.3 187.3 141.0 160.3 -2.1% 134.7 -17.5% -295.0 - - <% of revenue> <37.7%> <39.2%> <40.3%> <33.9%> <35.8%> <31.1%> <33.5%> #DIV/0! United States 130.5 121.4 130.4 137.8 148.6 13.9% 153.2 26.2% -301.8 - - <% of revenue> <30.1%> <29.1%> <28.1%> <33.1%> <33.1%> <35.4%> <34.2%> #DIV/0! Europe and Canada 76.5 66.3 69.9 67.1 73.6 -3.8% 75.4 13.7% -148.9 - - <% of revenue> <17.6%> <15.9%> <15.0%> <16.1%> <16.4%> <17.4%> <16.9%> #DIV/0! Emerging Markets 63.3 65.7 77.5 70.4 65.8 4.0% 69.9 6.3% -135.7 - - <% of revenue> <14.6%> <15.8%> <16.7%> <16.9%> <14.7%> <16.1%> <15.4%> #DIV/0! Russia/CIS 12.8 12.7 16.1 16.0 17.0 33.1% 18.1 42.5% -35.1 - - <% of revenue> <3.0%> <3.0%> <3.5%> <3.8%> <3.8%> <4.2%> <4.0%> #DIV/0! Latin America 15.0 16.7 23.4 17.5 17.0 13.3% 19.1 14.3% -36.1 - - <% of revenue> <3.4%> <4.0%> <5.0%> <4.2%> <3.8%> <4.4%> <4.1%> #DIV/0! Asia 27.5 28.0 30.7 26.7 25.2 -8.6% 24.0 -14.1% -49.2 - - <% of revenue> <6.3%> <6.7%> <6.6%> <6.4%> <5.6%> <5.5%> <5.6%> #DIV/0! Other 8.0 8.4 7.4 10.3 6.6 -17.0% 8.7 3.9% -15.3 - - <% of revenue> <1.8%> <2.0%> <1.6%> <2.5%> <1.5%> <2.0%> <1.7%> #DIV/0! Royalty income and service income 12.4 16.7 19.8 11.2 30.3 144.1% 12.8 -23.4% -43.2 - - *1 Revenue amount is classified into countries or regions based on the customer location.